From OHC
September 27, 2017
Leukemia is cancer of the blood cells. In 2017, there are an estimated 363,794 people living with, or in remission from, leukemia in the US.
Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. In 2017, there are an estimated 816,634 people living with, or in remission from, lymphoma in the US.
Why is there a push to increase awareness about these diseases? Awareness and education lead to more support. More support allows for more research. And research leads to new and better treatments, and survival rates are improving.
Survival Rates Have Greatly Improved.
The 5-year overall survival rate for Leukemia has more than quadrupled since 1960.
The 5-year relative survival rate for people with Hodgkin Lymphoma has more than doubled since 1960. In fact, Hodgkin Lymphoma is now considered to be one of the most curable forms of cancer.
The 5-year relative survival rate for people with Non-Hodgkin Lymphoma has risen to 72.6 percent from 2006 to 2012.
Research is working.
A Partnership Focused on Eradication.
At OHC, our search for new treatments is relentless. Our drive to provide superior care runs deep. And our fight against cancer is personal. OHC is known for delivering clinical excellence combined with unmatched personal support in neighborhoods throughout the region, surrounding patients with everything they need to focus on what matters most: beating cancer.
The mission of the Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. LLS research investment has played a critical role in advancing therapies for blood cancer patients, including targeted and immunotherapies.
With similar visions of a cancer-free world, it was an easy decision to support LLS in increasing awareness and education of leukemia and lymphoma. One of the best, most impactful ways to support the work of LLS is through their annual Light The Night event.
OHC Oncologist Dr. James Essell with a patient.
Join us to “Light The Night.”
Funding cutting-edge research and providing support services to patients and their families during their cancer journey requires resources. In order to fuel our mission, we need participants like you to help raise critical dollars. Here are just a few examples of how these funds make a difference:
- In communities across the country, LLS support groups provide patients and their families with a place to listen, learn and share with others in the same situation.
- Cancer can be overwhelming. But help is just a phone call away. LLS information resource specialists help educate and empower patients with individualized disease information and treatment options.
- In fiscal year 2016, LLS invested $49.3 million in blood cancer research. LLS funds breakthrough therapies for patients with blood cancers that are saving lives today.
The Leukemia & Lymphoma Society’s Light The Night Walk brings light to the darkness of cancer by funding lifesaving research and support for people battling cancer. Family, friends and co-workers gather together to celebrate, honor or remember those touched by cancer. During the Walk, walkers carry illuminated lanterns in three colors: white lanterns are carried by survivors; red lanterns by supporters; gold lanterns are carried by those walking in memory of loved ones lost to cancer.
Registration is free, but walkers are encouraged to raise funds to support the mission. These efforts culminate in inspirational, memorable evening experiences filled with music, fireworks and empowering ceremonies honoring survivors and remembering those we have lost. Please join us and nearly $1M others in the 200 walks across North America.
You are Invited to Join Our Team!
OHC is once again pleased to support the local Light The Night Walk.
Thursday, October 19, 2017
Yeatman’s Cove
705 East Pete Rose Way
Cincinnati, Ohio 45202
Please join our team today, click here!
